Biogen: Biogen, a leading biotechnology company ... instructing them to produce specific proteins. Spark Therapeutics: Spark Therapeutics, a leading gene therapy company, utilizes viral vectors ...

Implied volatility metrics suggest that eurozone investors see plenty of risks on the horizon. This is not surprising given headlines from French and German politics and rising tensions in the ...

GitHub has unveiled GitHub Spark, a new AI tool set to transform the landscape of personalized application development. This innovative platform enables you to create, deploy, and share fully ...

We’ve seen quite a few experiments in this arena in recent months, but now, GitHub itself is throwing its weight behind this idea with the announcement of GitHub Spark at the company’s annual ...

Investors with a lot of money to spend have taken a bearish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company’s shares closed last Friday at $159.99. Don't Miss our Black Friday ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...